Chemical informatics uncovers a new role for moexipril as a novel inhibitor of cAMP phosphodiesterase-4 (PDE4)

Graphical abstract

[1]  Steven G Chrysant,et al.  Pharmacological profile and clinical use of moexipril , 2003, Expert review of cardiovascular therapy.

[2]  S. Christensen,et al.  1,4-Cyclohexanecarboxylates: potent and selective inhibitors of phosophodiesterase 4 for the treatment of asthma. , 1998, Journal of medicinal chemistry.

[3]  M. Giembycz,et al.  Cilomilast: a second generation phosphodiesterase 4 inhibitor for asthma and chronic obstructive pulmonary disease , 2001, Expert opinion on investigational drugs.

[4]  Michael J. Keiser,et al.  Prediction and evaluation of protein farnesyltransferase inhibition by commercial drugs. , 2010, Journal of medicinal chemistry.

[5]  H. R. Evans,et al.  Structural details on the binding of antihypertensive drugs captopril and enalaprilat to human testicular angiotensin I-converting enzyme. , 2004, Biochemistry.

[6]  R. W. Fleming,et al.  Synthesis of novel angiotensin converting enzyme inhibitor quinapril and related compounds. A divergence of structure-activity relationships for non-sulfhydryl and sulfhydryl types. , 1986, Journal of medicinal chemistry.

[7]  Michael M. Mysinger,et al.  Automated Docking Screens: A Feasibility Study , 2009, Journal of medicinal chemistry.

[8]  John D. Scott,et al.  The A-kinase-anchoring protein AKAP-Lbc facilitates cardioprotective PKA phosphorylation of Hsp20 on Ser(16). , 2012, The Biochemical journal.

[9]  Tudor I. Oprea,et al.  Quantifying the Relationships among Drug Classes , 2008, J. Chem. Inf. Model..

[10]  Michael J. Keiser,et al.  Predicting new molecular targets for known drugs , 2009, Nature.

[11]  G. Nahas,et al.  Cyclic phosphodiesterase activity and the action of papaverine. , 1970, Biochemical and biophysical research communications.

[12]  E. Bateman,et al.  Roflumilast—an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial , 2005, The Lancet.

[13]  Michael J. Keiser,et al.  Relating protein pharmacology by ligand chemistry , 2007, Nature Biotechnology.

[14]  Domenico Spina,et al.  Selective PDE inhibitors as novel treatments for respiratory diseases. , 2012, Current opinion in pharmacology.

[15]  M. Zaccolo,et al.  Disruption of the cyclic AMP phosphodiesterase-4 (PDE4)-HSP20 complex attenuates the β-agonist induced hypertrophic response in cardiac myocytes. , 2011, Journal of molecular and cellular cardiology.

[16]  J. Daly,et al.  4-(3-Cyclopentyloxy-4-methoxyphenyl)-2-pyrrolidone (ZK 62711): a potent inhibitor of adenosine cyclic 3',5'-monophosphate phosphodiesterases in homogenates and tissue slices from rat brain. , 1976, Molecular pharmacology.

[17]  J. O'Donnell,et al.  Antidepressant effects of inhibitors of cAMP phosphodiesterase (PDE4). , 2004, Trends in pharmacological sciences.

[18]  Kees Jalink,et al.  Detecting cAMP‐induced Epac activation by fluorescence resonance energy transfer: Epac as a novel cAMP indicator , 2004, EMBO reports.

[19]  G. Baillie,et al.  cAMP-Specific phosphodiesterase-4 enzymes in the cardiovascular system: a molecular toolbox for generating compartmentalized cAMP signaling. , 2007, Circulation research.

[20]  G. Baillie,et al.  Sub‐family selective actions in the ability of Erk2 MAP kinase to phosphorylate and regulate the activity of PDE4 cyclic AMP‐specific phosphodiesterases , 2000, British journal of pharmacology.

[21]  Jennifer E. Chubb,et al.  DISC1 and PDE4B Are Interacting Genetic Factors in Schizophrenia That Regulate cAMP Signaling , 2005, Science.

[22]  G. Baillie,et al.  The emerging role of HSP20 as a multifunctional protective agent. , 2011, Cellular signalling.

[23]  C. Lugnier.  Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents. , 2006, Pharmacology & therapeutics.

[24]  M. Houslay.  Underpinning compartmentalised cAMP signalling through targeted cAMP breakdown. , 2010, Trends in biochemical sciences.

[25]  Kam Y. J. Zhang,et al.  Structural basis for the activity of drugs that inhibit phosphodiesterases. , 2004, Structure.

[26]  D. Ukena,et al.  Zardaverine as a selective inhibitor of phosphodiesterase isozymes. , 1991, Biochemical pharmacology.

[27]  Kam Y. J. Zhang,et al.  Phosphodiesterase-4 as a potential drug target , 2005, Expert opinion on therapeutic targets.

[28]  R. Strickley,et al.  Diketopiperazine Formation, Hydrolysis, and Epimerization of the New Dipeptide Angiotensin-Converting Enzyme Inhibitor RS-10085 , 1987, Pharmaceutical Research.

[29]  B. Shoichet.  Screening in a spirit haunted world. , 2006, Drug discovery today.

[30]  H. Ke,et al.  Enantiomer discrimination illustrated by the high resolution crystal structures of type 4 phosphodiesterase. , 2006, Journal of medicinal chemistry.

[31]  J. Beavo,et al.  Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling. , 2007, Annual review of biochemistry.

[32]  D. Adams,et al.  Phosphodiesterase inhibitors. Part 1: Synthesis and structure-activity relationships of pyrazolopyridine-pyridazinone PDE inhibitors developed from ibudilast. , 2011, Bioorganic & medicinal chemistry letters.

[33]  Kam Y. J. Zhang,et al.  Keynote review: phosphodiesterase-4 as a therapeutic target. , 2005, Drug discovery today.

[34]  M. Houslay,et al.  A peripheral and an intrinsic enzyme constitute the cyclic AMP phosphodiesterase activity of rat liver plasma membranes. , 1980, The Biochemical journal.

[35]  S. Christensen,et al.  1,4‐Cyclohexanecarboxylates: Potent and Selective Inhibitors of Phosphodiesterase 4 for the Treatment of Asthma. , 1998 .

[36]  S. Vasudevan,et al.  Shape-based reprofiling of FDA-approved drugs for the H₁ histamine receptor. , 2012, Journal of medicinal chemistry.

[37]  Steve Gupta.  Side-effects of roflumilast , 2012, The Lancet.

[38]  John P. Overington,et al.  ChEMBL: a large-scale bioactivity database for drug discovery , 2011, Nucleic Acids Res..

[39]  Martin J. Lohse,et al.  Novel Single Chain cAMP Sensors for Receptor-induced Signal Propagation*♦ , 2004, Journal of Biological Chemistry.

[40]  T. Ashburn,et al.  Drug repositioning: identifying and developing new uses for existing drugs , 2004, Nature Reviews Drug Discovery.

[41]  Tudor I. Oprea,et al.  ChemInform Abstract: Quantifying the Relationships among Drug Classes. , 2008 .

[42]  M. Soares,et al.  Antimalarial activity of physalins B, D, F, and G. , 2011, Journal of natural products.

[43]  Ian McPhee,et al.  Long PDE4 cAMP specific phosphodiesterases are activated by protein kinase A‐mediated phosphorylation of a single serine residue in Upstream Conserved Region 1 (UCR1) , 2002, British journal of pharmacology.

[44]  M. Houslay,et al.  In resting COS1 cells a dominant negative approach shows that specific, anchored PDE4 cAMP phosphodiesterase isoforms gate the activation, by basal cyclic AMP production, of AKAP-tethered protein kinase A type II located in the centrosomal region. , 2005, Cellular signalling.

[45]  G. Baillie.  Compartmentalized signalling: spatial regulation of cAMP by the action of compartmentalized phosphodiesterases , 2009, The FEBS journal.

[46]  Joseph Markowitz,et al.  Crystal structure of phosphodiesterase 4D and inhibitor complex1 , 2002, FEBS letters.

[47]  Charles C. Persinger,et al.  How to improve R&D productivity: the pharmaceutical industry's grand challenge , 2010, Nature Reviews Drug Discovery.

[48]  E. Bateman,et al.  Roflumilast—An oral anti-inflammatory treatment for chronic obstructive pulmonary disease: A randomised controlled trial: The Lancet 2005;366(9485):563–71. , 2005 .

[49]  G. Baillie,et al.  Remodelling of the PDE4 cAMP phosphodiesterase isoform profile upon monocyte‐macrophage differentiation of human U937 cells , 2004, British journal of pharmacology.

[50]  Ryan G. Coleman,et al.  ZINC: A Free Tool to Discover Chemistry for Biology , 2012, J. Chem. Inf. Model..

[51]  A. Patchett,et al.  Recent developments in the design of angiotensin‐converting enzyme inhibitors , 1985, Medicinal research reviews.